| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $3.3M | 0.00% | 1.18M | −32% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NKTX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 17, 2026 | Hastings Paul JChief Executive Officer | Sale at price 2.71 per share. | 1.8K | $4.81K |
| Jan 14, 2026 | Hastings Paul JChief Executive Officer | Sale at price 2.07 per share. | 26K | $53.91K |
| Jan 14, 2026 | Mahmood Nadir AhmeduddinPresident | Sale at price 2.07 per share. | 5.6K | $11.69K |
| Jan 5, 2026 | Hastings Paul JChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 94K | — |
| Jan 5, 2026 | Mahmood Nadir AhmeduddinPresident | Stock Award(Grant) at price 0.00 per share. | 80K | — |
| Jan 5, 2026 | Rose Shawn MarshallOfficer | Stock Award(Grant) at price 0.00 per share. | 70K | — |
| Jun 17, 2025 | Hastings Paul JChief Executive Officer | Sale at price 1.79 per share. | 1.8K | $3.20K |
| Jan 14, 2025 | Brandenberger Ralph ErikChief Technology Officer | Sale at price 2.20 per share. | 7.4K | $16.38K |
| Jan 14, 2025 | Shook David M.D.Officer | Sale at price 2.20 per share. | 8.6K | $19.00K |
| Jan 14, 2025 | Levin AlyssaChief Financial Officer | Sale at price 2.20 per share. | 5.8K | $12.84K |
| Jan 14, 2025 | Hastings Paul JChief Executive Officer | Sale at price 2.20 per share. | 17.4K | $38.23K |
| Jan 14, 2025 | Hager Alicia JOfficer | Sale at price 2.20 per share. | 9.6K | $21.09K |
| Jan 2, 2025 | Hastings Paul JChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 94.5K | — |
| Jan 2, 2025 | Hager Alicia JOfficer | Stock Award(Grant) at price 0.00 per share. | 52.5K | — |
| Jan 2, 2025 | Mahmood Nadir AhmeduddinPresident | Stock Award(Grant) at price 0.00 per share. | 62K | — |
| Jan 2, 2025 | Brandenberger Ralph ErikOfficer | Stock Award(Grant) at price 0.00 per share. | 52.5K | — |
| Jan 2, 2025 | Shook David M.D.Officer | Stock Award(Grant) at price 0.00 per share. | 59K | — |
| Jan 2, 2025 | Levin AlyssaChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 52.5K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 20.0 | 21.6 | -21.9 | 31.3 | 17.3 | -12.9 | -26.1 | 29.7 | -3.3 | -19.8 | +13.5% | ||
| 2025 | -6.0 | -25.2 | 5.1 | 15.2 | -17.9 | -4.6 | 30.7 | -2.3 | -2.4 | 1.9 | -10.4 | -2.1 | −25.7% |
| 2024 | 37.0 | 33.6 | -10.5 | -38.2 | 1.6 | -13.0 | 8.8 | -17.4 | -14.9 | -31.9 | -6.8 | -13.2 | −62.3% |
| 2023 | -11.0 | -21.2 | -15.5 | 39.4 | -6.7 | -52.6 | 4.6 | -24.9 | -19.2 | 46.0 | 30.0 | 150.0 | +10.2% |
| 2022 | -35.4 | -8.6 | 25.6 | 62.0 | -21.7 | -14.6 | 9.7 | 6.5 | -8.5 | -4.2 | -32.8 | -29.4 | −61.0% |
| 2021 | -35.5 | 22.9 | -32.5 | -3.2 | -23.5 | 30.1 | 0.2 | 1.8 | -14.0 | -43.6 | 1.3 | -3.4 | −75.0% |
| 2020 | -4.3 | 22.0 | -4.5 | 15.9 | 84.7 | +138.7% |
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Buy / hold / sell counts